Navigation Links
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Date:6/8/2009

xantrone in particular including, without limitation, the potential failure of pixantrone to prove safe and effective for treatment of relapsed aggressive NHL as determined by the FDA, the failure of pixantrone to have a low cardiotoxicity profile or to produce low cardiac toxicity, the failure of pixantrone to produce high rates of overall response including high rates of complete responses , the company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: deramian@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100

    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
10. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
11. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 FDNA® ... analysis will exhibit at the 2014 ASHG meeting, booth ... FDNA will present the latest version of Face2Gene - ... facial analysis technology. Face2Gene facilitates the detection of facial ... facial photos. The new version of Face2Gene ...
(Date:9/23/2014)... HACKENSACK, N.J. , Sept. 23, 2014   ... million in a planned $7 million Series A funding ... participation from Med-Metrix. COTA is the first big data ... outcomes data and cost analysis for cancer care in ... funds will be used to expand development of the ...
(Date:9/23/2014)... 2014 Cerevast Therapeutics Inc., a privately ... of the first interim analysis of its ongoing ... Clotbust ER TM ultrasonic headframe ... independent Data Safety Monitoring Board (DSMB) has recommended ... "Clearing the pre-specified futility threshold and four independent ...
Breaking Medicine Technology:FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 2Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 3
... May 3, 2012 Valeant Pharmaceuticals International, Inc. ... announced today that Valeant has agreed to acquire ... specialty pharmaceutical company focused on skincare products, for ... attainment of future revenue targets.  University Medical,s main ...
... Medical Group Inc. (Nasdaq: WWIN ) ("Winner ... retailer of high-quality medical dressings and consumer products made ... financial results for its second quarter 2012 on May ... conference call to discuss these results. Date ...
Cached Medicine Technology:Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical 2Winner Medical Group Inc. to Host Second Quarter 2012 Earning Conference Call on Thursday, May 10, 2012 at 9:00 p.m. EDT 2
(Date:9/23/2014)... who are already obese as teenagers could grow up ... peers of normal weight. So says Petter Lundborg of ... Rooth of Linneas University and Lund University, all in ... United Kingdom and the United States, and the results ... , The researchers analyzed large-scale data of 145,193 Swedish-born ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has recently ... services in Vancouver, BC. The company will provide services ... small maintenance project or a large-scale new installation project, ... the needs of the individual commercial client. Pro Ace ... an affordable price. As a result, businesses of all ...
(Date:9/23/2014)... 2014 The Sloane Clinic™, a ... and Malaysia providing advanced aesthetic dermatology and cosmetic ... its impressive skin care repertoire. Specially formulated with ... against the evil forces of aging, acne and ... this new addition is revolutionizing the way we ...
(Date:9/23/2014)... New York, New York (PRWEB) September 23, 2014 ... move forward in courts around the country, Bernstein Liebhard ... District Court, Middle District of Florida on September 19th, ... claims from a case filed in that jurisdiction on ... breast growth) and other complications due to his use ...
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... drugs while in the hospital for a hemorrhagic stroke -- ... four times more likely to survive than people who weren,t ... taking the commonly used drugs known as statins were also ... a rehabilitation facility, the study reports. When it comes ...
Breaking Medicine News(10 mins):Health News:Note to young men: Fat doesn't pay 2Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3
... to be under-enrolled in cancer clinical trials, according to a ... CANCER , a peer-reviewed journal of the American Cancer ... to ensure that oncologists know the true effects of treatments ... National Institutes of Health called for clinical trials to include ...
... A local leading ... surgery and what benefits these techniques have for the patient. , ... Manchester, UK (PRWeb UK) 07 June, 2009 -- Cosmetic ... providers of cosmetic surgery than ever before. As a result there is an inherent danger ...
... June 7 There is no difference in mortality among ... received prompt bypass surgery or angioplasty compared to drug therapy ... with both conditions. The study, which was led by investigators ... published in the June 11 issue of the New ...
... ... clinic will be built in Belize City, Belize. , ... Sioux Falls, SD (Vocus) June 7, 2009 -- Children in Central ... today its first international children,s clinic will be built in Belize City, Belize. The new ...
... , NEW ORLEANS, June 6 Catholic health ministry leaders ... Catholic Health Assembly, "In Our Hands: Changing Ourselves, Our Communities, ... the Catholic Health Association of the United States (CHA), is ... across the nation. They come together to share their wisdom, ...
... ... leading organization of plastic surgeons indicates a 162 percent increase in cosmetic surgery since ... with new technologies to treat patients who want to improve their appearance without anyone ... ...
Cached Medicine News:Health News:Women under-represented in most cancer research 2Health News:Latest Developments In Facelift Surgery - Expert Opinion by Mr James Murphy 2Health News:Latest Developments In Facelift Surgery - Expert Opinion by Mr James Murphy 3Health News:Death rates same for diabetes and heart disease patients receiving drug therapy or surgery 2Health News:Sanford Health Announces Sanford Children's Clinic Belize 2Health News:Sanford Health Announces Sanford Children's Clinic Belize 3Health News:Sanford Health Announces Sanford Children's Clinic Belize 4Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 2Health News:2009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 3Health News:Sacramento Plastic Surgeon Charles Perry, MD Embraces Innovative Technologies to Improve Appearance and Self-Esteem 2Health News:Sacramento Plastic Surgeon Charles Perry, MD Embraces Innovative Technologies to Improve Appearance and Self-Esteem 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: